文献速递造血干细胞移植与细胞治疗

移植后环磷酰胺预防移植物抗宿主病:前瞻性随机HOVON-96试验结果

Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial.
PubMed 文献 · Blood Adv · 2022-01-01

这项前瞻性随机多中心3期试验纳入160例高危血液恶性肿瘤患者,按1:2随机分配至环孢素A/霉酚酸组或移植后环磷酰胺/环孢素A组,实际移植151例(52例 vs 99例)。6个月2-4级急性GVHD累积发生率48% vs 30%(HR 0.48,95%CI 0.29-0.82,P=0.007),2年广泛型慢性GVHD累积发生率48% vs 16%(HR 0.36,95%CI 0.21-0.64,P<0.001),1年GRFS 21% vs 45%(P<0.001)。

要点

  • 移植后环磷酰胺联合短程环孢素A较环孢素A/霉酚酸显著降低6个月2-4级急性GVHD累积发生率(48% vs 30%,HR 0.48,P=0.007)。
  • 移植后环磷酰胺组2年广泛型慢性GVHD累积发生率显著低于对照组(48% vs 16%,HR 0.36,P<0.001)。
  • 1年无GVHD无复发生存(GRFS)在移植后环磷酰胺组为45%,对照组为21%(P<0.001)。

核心结论

  • 在非清髓性匹配相关或无关外周血异基因造血干细胞移植后,移植后环磷酰胺联合短程环孢素A较环孢素A/霉酚酸显著改善GRFS,归因于严重急性和慢性GVHD的显著减少。

研究设计与样本

  • 前瞻性随机、多中心、3期试验,2013年10月至2018年6月纳入160例高危血液恶性肿瘤且具有匹配相关或至少8/8 HLA匹配无关供者的患者,按1:2随机分配至环孢素A/霉酚酸组或移植后环磷酰胺/环孢素A组,实际移植151例(分别为52例 vs 99例)。

主要发现

  • 6个月2-4级急性GVHD累积发生率在环孢素A/霉酚酸组为48%,移植后环磷酰胺/环孢素A组为30%(HR 0.48,95%CI 0.29-0.82,P=0.007)。
  • 2年广泛型慢性GVHD累积发生率在环孢素A/霉酚酸组为48%,移植后环磷酰胺/环孢素A组为16%(HR 0.36,95%CI 0.21-0.64,P<0.001)。
  • 1年GRFS估计值在环孢素A/霉酚酸组为21%(11%-32%),移植后环磷酰胺/环孢素A组为45%(35%-55%),P<0.001。
  • 中位随访56.4个月,两治疗组间复发发生率、无进展生存和总生存无显著差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Graft-versus-host disease (GVHD) is the most important complication of allogeneic hematopoietic stem cell transplantation (alloHSCT). We performed a prospective randomized, multicenter, phase 3 trial to study whether posttransplant cyclophosphamide (PT-Cy) combined with a short course of cyclosporine A (CsA) would result in a reduction of severe GVHD and improvement of GVHD-free, relapse-free survival (GRFS) as compared with the combination of CsA and mycophenolic acid (MPA) after nonmyeloablative (NMA) matched related and unrelated peripheral blood alloHSCT. Between October 2013 and June 2018, 160 patients diagnosed with a high-risk hematological malignancy and having a matched related or at least 8 out of 8 HLA-matched unrelated donor were randomized and allocated in a 1:2 ratio to CsA/MPA or PT-Cy/CsA; a total of 151 patients were transplanted (52 vs 99 patients, respectively). The cumulative incidence of grade 2 to 4 acute GVHD at 6 months was 48% in recipients of CsA/MPA vs 30% following PT-Cy/CsA (hazard ratio [HR], 0.48; 95% confidence interval [CI], 0.29-0.82; P = .007). The 2-year cumulative incidence of extensive chronic GVHD was 48% vs 16% (HR, 0.36; 95% CI, 0.21-0.64; P < .001). The 1-year estimate of GRFS was 21% (11% to 32%) vs 45% (35% to 55%), P < .001. With a median follow-up of 56.4 months, relapse incidence, progression-free survival, and overall survival were not significantly different between the 2 treatment arms. PT-Cy combined with a short course of CsA after NMA matched alloHSCT significantly improves GRFS due to a significant reduction in severe acute and chronic GVHD.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Broers AEC, de Jong CN, Bakunina K, et al. Posttransplant cyclophosphamide for prevention of graft-versus-host disease: results of the prospective randomized HOVON-96 trial. Blood Adv. 2022. PMID: 35143644. doi:10.1182/bloodadvances.2021005847

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。